- Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
- Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼
Key statistics
On Wednesday, Cabaletta Bio Inc (CABA:NSQ) closed at 7.55, 9.42% above its 52-week low of 6.90, set on Jun 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.39 |
---|---|
High | 7.81 |
Low | 7.24 |
Bid | 6.97 |
Offer | 7.55 |
Previous close | 7.39 |
Average volume | 1.84m |
---|---|
Shares outstanding | 48.28m |
Free float | 45.05m |
P/E (TTM) | -- |
Market cap | 356.76m USD |
EPS (TTM) | -1.73 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼